Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

MICROBiome-based biomarkers to PREDICT decompensation of liver cirrhosis and treatment response

Descripción del proyecto

Identificación de biomarcadores basados en microbiomas para la enfermedad hepática en fase terminal

La última fase de la enfermedad hepática es la cirrosis descompensada y la progresión hacia la insuficiencia hepática aguda sobre crónica (IHAC) que implica inflamación sistémica e insuficiencia orgánica y tiene un pronóstico desalentador. Cada vez más datos apuntan a que el microbioma intestinal participa en la cirrosis hepática, pero aún no se conocen las razones subyacentes a este proceso. MICROB-PREDICT es un programa de excelencia financiado por la Unión Europea que tiene como objetivo investigar el papel del microbioma en la interacción entre el intestino y el hígado. Sus investigadores identificarán biomarcadores basados en microbiomas asociados con la enfermedad hepática en fase terminal y generarán datos de grandes cohortes de pacientes. En conjunto, esta información permitirá una estratificación precisa de los pacientes y allanará el camino para terapias personalizadas.

Objetivo

Decompensation of liver cirrhosis and progression towards acute-on-chronic liver failure (ACLF) causes 1.2 million deaths/year. Microbiome is causally involved in cirrhosis progression and is for drugs the first interaction point with the patients. Drugs can alter the microbiome leading to unwanted effects or even facilitating their effects, but the microbiome metabolizes the drugs, shapes their effects and possibly determines the host response to drugs. As each person carries an individual microbiome, insight in these processes should help stratify or even personalize patient health care and treatment.
The aims of MICROB-PREDICT are 1) to better understand the role of microbiome and the gut-liver-axis interactome with respect to microbiome functionalities, 2) to identify and validate microbiome-based biomarkers and signatures for personalized prediction of decompensation and ACLF, and response to treatment, 3) to design three new tests as easy-to-use tools and point-of-care, smartphone-connected nanobiosensors, and 4) to validate them in a randomized controlled trial. MICROB-PREDICT will assemble existing data and samples from major microbiome initiatives in hepatology (12 international studies, >10,000 patients), and enrich them with holistic and in-depth analysis using cutting-edge multi-omics technologies of host and microbiome from different body sites in samples of >1,000 patients collected in a longitudinal manner with sequential visits and controlling for confounders.
MICROB-PREDICT results will foster more accurate, personalized risk stratification and significant steps towards personalized treatment of decompensated cirrhosis and ACLF. World-leading microbiome specialists, technology leaders and clinical experts make this a programme of scientific excellence; patient organisations (ELPA) and the European Association for the study of the Liver (EASL) will channel our results into a powerful dissemination, communication and exploitation programme.

Convocatoria de propuestas

H2020-SC1-BHC-2018-2020

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-SC1-2018-Single-Stage-RTD

Régimen de financiación

RIA - Research and Innovation action

Coordinador

EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC LIVER FAILURE (EF-CLIF)
Aportación neta de la UEn
€ 2 283 191,11
Dirección
TRAVESSERA DE GRACIA 11, 7TH FLOOR
08021 Barcelona
España

Ver en el mapa

Región
Este Cataluña Barcelona
Tipo de actividad
Research Organisations
Enlaces
Coste total
€ 2 283 191,11

Participantes (23)